Cell APC and Open Access: The $11,400 Fee, Elsevier Agreements, and Your Real Options

Cell operates as a hybrid journal with two tracks:

1. Subscription track (default, $0): Your article is published behind the Elsevier/Cell Press paywall. Institutional libraries pay for access. You pay nothing.

1. Gold open access track ($11,400): Your article is immediately free to read for everyone. You choose a Creative Commons license (CC BY or CC BY-NC-ND).

This is the same structure as Nature, but with one critical difference: institutional coverage can be title-specific.

Here's the problem many researchers don't discover until after acceptance: Cell Press coverage is not guaranteed by an ordinary Elsevier Read & Publish agreement.

Elsevier has negotiated transformative agreements with institutions worldwide. Some agreements cover large sets of Elsevier hybrid journals, while Cell Press, Lancet, and Clinics titles may be excluded, capped, or handled under separate terms. The only reliable answer is the title-level agreement record your library uses at the time your article is accepted.

What this means in practice:

Some institutions have negotiated separate Cell Press inclusion into their Elsevier agreements. Others have article caps, funder-only coverage, or no Cell Press coverage at all.

Before choosing OA at Cell, check with your library. Specifically ask: "Does our Elsevier agreement cover Cell Press titles?" Don't assume it does because your other Elsevier publications were covered.

Cell Press has a less transparent waiver path than some fully open-access publishers, because Cell remains hybrid and the subscription route is available without an author publication fee. Still, check all three coverage paths before treating $11,400 as a personal out-of-pocket cost:

Country-based waivers and discounts:

Elsevier states that open-access waivers and Research4Life-linked discounts are available for eligible authors in lower-income countries. Because hybrid-journal treatment differs from fully open-access-journal treatment, confirm the Cell-specific result in the rights and access workflow after acceptance.

Institutional agreements and Read and Publish coverage:

Your library may have an Elsevier or Cell Press agreement that covers eligible corresponding authors, eligible article types, or a limited annual quota. Ask for the title-level Cell record, not just whether your institution has an Elsevier agreement.

Financial hardship or case-by-case support:

If no country, funder, or institutional route covers the APC, contact the journal or publisher support team before completing open-access licensing. Case-by-case hardship support is not guaranteed, so preserve the subscription route as the fallback if immediate OA is not required.

Funder payment:

Some funders will pay gold-OA APCs only when the license, repository, and acknowledgment rules match their policy. If your grant requires CC BY, make that license check before you select CC BY-NC-ND.

Cell APC pages go stale quickly because the price, tax handling, and agreement coverage can move on different schedules. We verified this page on July 8, 2026 against sciencedirect.com and Cell author information, then treated any institution-specific coverage as something the author must confirm locally.

The guardrail is simple: use the current publisher portal for the number, and use your institution's agreement checker for whether that number actually reaches your lab.

If Cell at $11,400 feels steep, here's how it compares to the rest of the Cell Press family:

The pattern: flagship and specialty hybrid journals cluster around $9,350-$11,400, while the fully OA titles (Cell Reports, Cell Reports Medicine, Cell Genomics) are $5,790.

The APC is only rational if the manuscript has a realistic Cell-level shot. Cell's current metric profile supports the journal's premium position, but it should not be used as a reason to submit a paper that lacks broad biological consequence.

Compared to previous JCR cycles, Cell's JIF is down from the pandemic-inflated highs but still sits in elite biology-journal territory. That movement does not change the submission bar. It only reinforces the same practical rule: pay for immediate OA only after the paper looks like a credible Cell submission, not simply because the journal metric is attractive. For the full metric history, use the dedicated Cell JIF guide.

In our pre-submission review work with Cell-targeted manuscripts, the APC question usually appears after a deeper fit problem. The team may have a grant that can absorb $11,400, but the paper still needs a Cell-level conceptual claim, not only strong technical execution.

The most common pattern is APC solved before editorial fit. Authors confirm that a library or funder can pay, then discover at desk review that the abstract reads like a specialty-journal paper rather than a broad Cell story. The money decision should come after the fit decision.

A second pattern is coverage checked too late. The corresponding author assumes an Elsevier agreement covers Cell because it covered a different Elsevier title. Cell Press coverage can be separate, capped, or article-type limited, so the safe step is a title-level check before acceptance.

A third pattern is license choice treated as paperwork. For Plan S, UKRI, Wellcome, and similar policies, CC BY may be required. If the team picks CC BY-NC-ND because it feels safer, the publication can still create a compliance problem even after the APC is paid.

The practical sequencing is therefore evidence first, invoice second: test the Cell story, confirm the agreement path, then decide whether immediate OA adds enough value over the free subscription route.

One useful internal check is to separate the manuscript into components before the fee discussion. The abstract should state a field-level claim in the first few sentences, the main figures should show why the mechanism or biological result changes the reader's model, the methods and controls should remove obvious reviewer objections, and the cover letter should make the Cell-specific breadth case without overselling. If those pieces still read like a narrower specialty-journal submission, the APC decision is premature even when the payment route is solved.

Cell rewards that component alignment more than a polished payment plan.

Across our analysis of Cell-targeted submissions, we observe that funding certainty rarely rescues a manuscript whose central claim, figure sequence, and cover-letter argument do not already read as Cell-level.

Manusights internal analysis and review data point to the same order: we have found that the abstract, figure logic, and funding route need separate checks before the APC decision.

Cell supports both CC BY and CC BY-NC-ND licenses. Plan S funders require CC BY. If your funder is a cOAlition S member, you must select CC BY during the licensing stage. The CC BY-NC-ND option does not satisfy Plan S. For NIH-funded researchers: Cell allows deposit of the accepted manuscript in PubMed Central after a 12-month embargo. If you don't need immediate OA, this route is free.

Cell doesn't charge page fees, color figure charges, or submission fees. The APC is the only publication charge. But watch for these:

• Tax: VAT or other sales tax applies in many jurisdictions. In the EU, this can add 15-25% to the listed price, making the effective cost $13,000-$14,000.

• Graphical abstract: Cell requires a graphical abstract for all research articles. Creating this isn't a journal fee, but if you hire a scientific illustrator, budget $200-$500.

• License lock-in: If you select CC BY-NC-ND at the licensing stage and later realize your funder requires CC BY, changing the license post-publication requires publisher approval and isn't guaranteed.

• Embargo timing: If you publish via the subscription track and deposit in PMC, the 12-month clock starts from the publication date, not the acceptance date. Papers that spend months in production have a longer total wait.

Cell's APC situation is straightforward but inconvenient. You have two options:

1. Publish for free via subscription. Your paper is in Cell, fully indexed, fully citable. It goes behind the paywall. After 12 months, you can deposit in PMC.

1. Pay $11,400 for immediate OA. Your paper is free to read from day one. Check first whether your institution or funder covers this.

The most common mistake: assuming your Elsevier institutional deal covers Cell Press. It might, but only a title-level agreement check proves it. Ask your library before you commit to OA.

If you're deciding whether Cell is the right target for your manuscript, the APC is secondary to getting past the editors. Cell desk-rejects roughly 70% of submissions, and the editorial bar is whether your findings change how biologists think about a fundamental process. Cell submission readiness check to check your paper's fit before submitting.

Worth paying if:

• Your funder mandates open access (check Plan S / cOAlition S requirements)

• An institutional Read & Publish agreement covers the fee

• Open access visibility meaningfully benefits your research area

• The APC fits within your grant budget

Consider alternatives if:

• The APC is a personal out-of-pocket expense

• A subscription option or green OA (preprint + embargo) satisfies your funder

• Another OA journal with a lower APC would provide similar visibility

For a manuscript-specific signal before you submit, run a Cell submission readiness check.

Or see example reports before you finalize.